Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxel-cisplatin combination chemotherapy: single institution experience


KOCAK M., MAYADAGLI A., OZKAN A., PARLAK C., DEMIR O., MARTI A., et al.

JOURNAL OF BUON, cilt.12, ss.471-476, 2007

  • Cilt numarası: 12 Konu: 4
  • Basım Tarihi: 2007
  • Dergi Adı: JOURNAL OF BUON
  • Sayfa Sayısı: ss.471-476

Özet

Purpose: Despite advances in the detection and treatment, the long-term survival of patients with advanced non-small cell lung cancer (NSCLC) remains poor, with a 5-year overall survival (OS) of less than 5%. We conducted this observational study to determine the influence of docetaxel plus cisplatin combination chemotherapy on response, time to progression (TTP) and OS, and to evaluate its tolerability in chemotherapy-naive patients with metastatic NSCLC.